AWM
FHTX icon

Avior Wealth Management’s Foghorn Therapeutics FHTX Stock Holding History

Avior Wealth Management’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3
Closed -$20 – 2774
2024
Q1 		$20 Buy
+3
New +$17 ﹤0.01% 3686

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Avior Wealth Management's FHTX Position: Q2 2024 in Review

Avior Wealth Management sold out of Foghorn Therapeutics (FHTX) in Q2 2024, closing a stake of 3 shares — an estimated $20 sold.

Avior Wealth Management first reported a position in FHTX in Q1 2024 and held it in 1 quarter. The position peaked at $20 in Q1 2024. 72 funds tracked by Wall St. Rank hold FHTX as of Q2 2024.

  • Avior Wealth Management reported no remaining Foghorn Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Avior Wealth Management sold 3 Foghorn Therapeutics shares in Q2 2024, an estimated $20.
  • Avior Wealth Management first reported a position in Foghorn Therapeutics in Q1 2024 and held it in 1 quarter.
  • Avior Wealth Management's Foghorn Therapeutics position peaked at $20 in Q1 2024.
  • 72 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2024.

Based on Avior Wealth Management's 13F filing for Q2 2024, filed 13 Aug 2024.